Product Information
LYBALVI 10-10 MG TABLET is a brand product labeled by Alkermes, Inc., priced at $55.0970 per EA under NDC 65757065242. Its NADAC has been published 237 times since Mar 23, 2022.
FDA first approved this application on May 28, 2021.
Strength
10; 10 mg/1; mg/1
Manufacturer
Alkermes, Inc.NDC
65757065242
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
OLANZAPINE; SAMIDORPHAN L-MALATEApproval Type
New Drug (NDA)
FDA Application
NDA213378FDA Approved
5/28/2021
On Market Since
9/20/2021
Pharmacological Classes
Price Statistics
The NADAC for LYBALVI 10-10 MG TABLET has been published 237 times since Mar 23, 2022, and over the history we have for it it has risen 24.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $55.0970 per EA |
|---|---|
| All-time high | $55.1568 (Aug 12, 2026) |
| All-time low | $44.3874 (Mar 23, 2022) |
| 52-week high | $55.1568 |
| 52-week low | $52.4897 |
| Median price | $50.0664 |
| Average price | $50.0125 |
| Largest weekly change | +5.5% (Nov 23, 2022) |
| Weeks tracked | 237 |
| Tracking since | Mar 23, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the olanzapine and samidorphan L-malate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Alkermes, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
olanzapine and samidorphan L-malate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Atypical Antipsychotic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LYBALVI 10-10 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LYBALVI 10-10 MG TABLET, manufactured by Alkermes, Inc., is $55.0970 per EA (NDC 65757065242), effective Sep 30, 2026.
How has the price of LYBALVI 10-10 MG TABLET changed over time?
Over the history we have for it, the NADAC for LYBALVI 10-10 MG TABLET has risen 24.1%. It has been tracked across 237 weekly CMS publications since Mar 23, 2022.
What are the highest and lowest recorded NADAC prices for LYBALVI 10-10 MG TABLET?
Since Mar 23, 2022, the NADAC for LYBALVI 10-10 MG TABLET has ranged from a low of $44.3874 (Mar 23, 2022) to a high of $55.1568 (Aug 12, 2026), with a median of $50.0664 per EA.
Are there cheaper alternatives to LYBALVI 10-10 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of LYBALVI 10-10 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures LYBALVI 10-10 MG TABLET?
LYBALVI 10-10 MG TABLET (NDC 65757065242) is labeled by Alkermes, Inc., and CMS classifies it as a brand product.